163 related articles for article (PubMed ID: 35967315)
61. HIV Suppression Restores the Lung Mucosal CD4+ T-Cell Viral Immune Response and Resolves CD8+ T-Cell Alveolitis in Patients at Risk for HIV-Associated Chronic Obstructive Pulmonary Disease.
Popescu I; Drummond MB; Gama L; Lambert A; Hoji A; Coon T; Merlo CA; Wise RA; Keruly J; Clements JE; Kirk GD; McDyer JF
J Infect Dis; 2016 Nov; 214(10):1520-1530. PubMed ID: 27613775
[TBL] [Abstract][Full Text] [Related]
62. Biological determinants of immune reconstitution in HIV-infected patients receiving antiretroviral therapy: the role of interleukin 7 and interleukin 7 receptor α and microbial translocation.
Rajasuriar R; Booth D; Solomon A; Chua K; Spelman T; Gouillou M; Schlub TE; Davenport M; Crowe S; Elliott J; Hoy J; Fairley C; Stewart G; Cameron P; Lewin SR
J Infect Dis; 2010 Oct; 202(8):1254-64. PubMed ID: 20812848
[TBL] [Abstract][Full Text] [Related]
63. Antiretroviral therapy corrects HIV-1-induced expansion of CD8+ CD45RA+ CD2-) CD11a(bright) activated T cells.
Yin L; Rodriguez CA; Hou W; Potter O; Caplan MJ; Goodenow MM; Sleasman JW
J Allergy Clin Immunol; 2008 Jul; 122(1):166-72, 172.e1-2. PubMed ID: 18538835
[TBL] [Abstract][Full Text] [Related]
64. Predicting patterns of long-term CD4 reconstitution in HIV-infected children starting antiretroviral therapy in sub-Saharan Africa: a cohort-based modelling study.
Picat MQ; Lewis J; Musiime V; Prendergast A; Nathoo K; Kekitiinwa A; Nahirya Ntege P; Gibb DM; Thiebaut R; Walker AS; Klein N; Callard R;
PLoS Med; 2013 Oct; 10(10):e1001542. PubMed ID: 24204216
[TBL] [Abstract][Full Text] [Related]
65. Switch to second-line versus continued first-line antiretroviral therapy for patients with low-level HIV-1 viremia: An open-label randomized controlled trial in Lesotho.
Amstutz A; Nsakala BL; Vanobberghen F; Muhairwe J; Glass TR; Namane T; Mpholo T; Battegay M; Klimkait T; Labhardt ND
PLoS Med; 2020 Sep; 17(9):e1003325. PubMed ID: 32936795
[TBL] [Abstract][Full Text] [Related]
66. Persistent low viral load on antiretroviral therapy is associated with T cell-mediated control of HIV replication.
Alatrakchi N; Duvivier C; Costagliola D; Samri A; Marcelin AG; Kamkamidze G; Astriti M; Agher R; Calvez V; Autran B; Katlama C
AIDS; 2005 Jan; 19(1):25-33. PubMed ID: 15627030
[TBL] [Abstract][Full Text] [Related]
67. Changes in CD4+ and CD8+ T cell subsets in response to highly active antiretroviral therapy in HIV type 1-infected patients with prior protease inhibitor experience.
Gray CM; Schapiro JM; Winters MA; Merigan TC
AIDS Res Hum Retroviruses; 1998 May; 14(7):561-9. PubMed ID: 9591710
[TBL] [Abstract][Full Text] [Related]
68. Archiving of mutations in HIV-1 cellular reservoirs among vertically infected adolescents is contingent with clinical stages and plasma viral load: Evidence from the EDCTP-READY study.
Fokam J; Mpouel Bala ML; Santoro MM; Takou D; Tala V; Beloumou G; Ngoufack ES; Chenwi C; Pabo Willy Leroi T; Njume D; Teto G; Dambaya B; Djupsa S; Sosso S; Ateba F; Kamta C; Bala L; Njom Nlend AE; Koki Ndombo P; Colizzi V; Perno CF; Ndjolo A
HIV Med; 2022 Jul; 23(6):629-638. PubMed ID: 34951111
[TBL] [Abstract][Full Text] [Related]
69. CD4/CD8 Ratio Recovery of Children and Adolescents Living With HIV With Virological Suppression: A Prospective Cohort Study.
Han WM; Apornpong T; Handoko R; Jantarabenjakul W; Gatechompol S; Ubolyam S; Kerr SJ; Avihingsanon A; Ruxrungtham K; Phanuphak P; Puthanakit T
J Pediatric Infect Dis Soc; 2021 Mar; 10(2):88-96. PubMed ID: 32188991
[TBL] [Abstract][Full Text] [Related]
70. Composition and function of T cell subpopulations are slow to change despite effective antiretroviral treatment of HIV disease.
Emu B; Moretto WJ; Hoh R; Krone M; Martin JN; Nixon DF; Deeks SG; McCune JM
PLoS One; 2014; 9(1):e85613. PubMed ID: 24465619
[TBL] [Abstract][Full Text] [Related]
71. Short-term and long-term clinical and immunological consequences of stopping antiretroviral therapy in HIV-infected patients with preserved immune function.
Imaz A; Olmo M; Peñaranda M; Gutiérrez F; Romeu J; Larrousse M; Domingo P; Oteo JA; Curto J; Vilallonga C; Masiá M; López-Aldeguer J; Iribarren JA; Podzamczer D;
Antivir Ther; 2013; 18(1):125-30. PubMed ID: 22805174
[TBL] [Abstract][Full Text] [Related]
72. Effects of recombinant human interleukin 7 on T-cell recovery and thymic output in HIV-infected patients receiving antiretroviral therapy: results of a phase I/IIa randomized, placebo-controlled, multicenter study.
Lévy Y; Sereti I; Tambussi G; Routy JP; Lelièvre JD; Delfraissy JF; Molina JM; Fischl M; Goujard C; Rodriguez B; Rouzioux C; Avettand-Fenoël V; Croughs T; Beq S; Morre M; Poulin JF; Sekaly RP; Thiebaut R; Lederman MM
Clin Infect Dis; 2012 Jul; 55(2):291-300. PubMed ID: 22550117
[TBL] [Abstract][Full Text] [Related]
73. CD161
Li X; Liu Z; Li Q; Hu R; Zhao L; Yang Y; Zhao J; Huang Z; Gao H; Li L; Cai W; Deng K
mBio; 2019 Oct; 10(5):. PubMed ID: 31594817
[TBL] [Abstract][Full Text] [Related]
74. Brief Report: Polymorphisms in TNF-α/TNFR1 Pathway Genes Are Associated With CD4+ T-Cell Recovery in HIV-1-Infected Individuals on Antiretroviral Therapy.
Celerino da Silva R; Alves NMP; Gondim Silva ML; Agrelli A; Coelho AVC; Guimarães RL; Arraes LC; Crovella S; Brandão LAC
J Acquir Immune Defic Syndr; 2021 Nov; 88(3):322-327. PubMed ID: 34267056
[TBL] [Abstract][Full Text] [Related]
75. Assessment of chloroquine as a modulator of immune activation to improve CD4 recovery in immune nonresponding HIV-infected patients receiving antiretroviral therapy.
Routy JP; Angel JB; Patel M; Kanagaratham C; Radzioch D; Kema I; Gilmore N; Ancuta P; Singer J; Jenabian MA
HIV Med; 2015 Jan; 16(1):48-56. PubMed ID: 24889179
[TBL] [Abstract][Full Text] [Related]
76. Determinants of CD4+ T cell recovery during suppressive antiretroviral therapy: association of immune activation, T cell maturation markers, and cellular HIV-1 DNA.
Goicoechea M; Smith DM; Liu L; May S; Tenorio AR; Ignacio CC; Landay A; Haubrich R
J Infect Dis; 2006 Jul; 194(1):29-37. PubMed ID: 16741879
[TBL] [Abstract][Full Text] [Related]
77. Two Distinct Mechanisms Leading to Loss of Virological Control in the Rare Group of Antiretroviral Therapy-Naive, Transiently Aviremic Children Living with HIV.
Vieira VA; Adland E; Grayson NE; Csala A; Richards F; Dacon C; Athavale R; Tsai MH; D'Souza R; Muenchhoff M; Bonsall D; Jooste P; Goulder PJR
J Virol; 2022 Jan; 96(2):e0153521. PubMed ID: 34757843
[TBL] [Abstract][Full Text] [Related]
78. Which HIV-infected adults with high CD4 T-cell counts benefit most from immediate initiation of antiretroviral therapy? A post-hoc subgroup analysis of the START trial.
Molina JM; Grund B; Gordin F; Williams I; Schechter M; Losso M; Law M; Ekong E; Mwelase N; Skoutelis A; Wiselka MJ; Vandekerckhove L; Benfield T; Munroe D; Lundgren JD; Neaton JD;
Lancet HIV; 2018 Apr; 5(4):e172-e180. PubMed ID: 29352723
[TBL] [Abstract][Full Text] [Related]
79. Increased rate of CD4+ T-cell decline and faster time to antiretroviral therapy in HIV-1 subtype CRF01_AE infected seroconverters in Singapore.
Ng OT; Lin L; Laeyendecker O; Quinn TC; Sun YJ; Lee CC; Leo YS
PLoS One; 2011 Jan; 6(1):e15738. PubMed ID: 21298051
[TBL] [Abstract][Full Text] [Related]
80. Reduced markers of HIV persistence and restricted HIV-specific immune responses after early antiretroviral therapy in children.
Ananworanich J; Puthanakit T; Suntarattiwong P; Chokephaibulkit K; Kerr SJ; Fromentin R; Bakeman W; Intasan J; Mahanontharit A; Sirivichayakul S; Chomont N;
AIDS; 2014 Apr; 28(7):1015-20. PubMed ID: 24384692
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
